As shown in Figure 1, anti-PD-1/PD-L1 therapy can bind to PD-1 and PD-L1 correspondingly, further preventing the combination of PD-1 on the surface of T cells and PD-L1 on the surface of tumor cells (40). This evidence concerns the gene PDCD1 and neoplasm.